Tripos Faces Delisting From Nasdaq for Low Share Price, Market Cap | GenomeWeb
NEW YORK (GenomeWeb News) — Tripos today said it is in jeopardy of being delisted from the Nasdaq exchange for not maintaining the minimum market cap and minimum share bid price for 30 consecutive days.
The company said it has 90 days to regain market-cap compliance and 180 days to regain share-price compliance or it will be delisted from the market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.